These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11304903)

  • 41. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
    Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
    Humphrey PP; Bountra C; Clayton N; Kozlowski K
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women.
    Carvalho DM; Lanchote VL; Filgueira GCO; Nardotto GHB; Duarte G; Cavalli RC; Moisés ECD
    Clin Pharmacol Ther; 2019 Apr; 105(4):1003-1008. PubMed ID: 30346625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alosetron does not affect the visceral perception of gastric distension in healthy subjects.
    Zerbib F; Bruley des Varannes S; Oriola RC; McDonald J; Isal JP; Galmiche JP
    Aliment Pharmacol Ther; 1994 Aug; 8(4):403-7. PubMed ID: 7986965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.
    Eap CB; Bondolfi G; Zullino D; Savary-Cosendai L; Powell-Golay K; Kosel M; Baumann P
    J Clin Psychopharmacol; 2001 Jun; 21(3):330-4. PubMed ID: 11386497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
    Jannuzzi G; Gatti G; Magni P; Spina E; Pacifici R; Zuccaro P; Torta R; Guarneri L; Perucca E
    Ther Drug Monit; 2002 Oct; 24(5):616-27. PubMed ID: 12352933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
    Fleishaker JC
    Clin Pharmacokinet; 2000 Dec; 39(6):413-27. PubMed ID: 11192474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia.
    Miranda A; Peles S; McLean PG; Sengupta JN
    Pain; 2006 Dec; 126(1-3):54-63. PubMed ID: 16844296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function.
    Levy NB; Blumenfield M; Beasley CM; Dubey AK; Solomon RJ; Todd R; Goodman A; Bergstrom RR
    Gen Hosp Psychiatry; 1996 Jan; 18(1):8-13. PubMed ID: 8666216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep.
    Kim J; Riggs KW; Rurak DW
    Drug Metab Dispos; 2004 Feb; 32(2):212-21. PubMed ID: 14744943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
    Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
    [No Abstract]   [Full Text] [Related]  

  • 56. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
    Berman SM; Chang L; Suyenobu B; Derbyshire SW; Stains J; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD; Mayer EA
    Gastroenterology; 2002 Oct; 123(4):969-77. PubMed ID: 12360456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women.
    Allard S; Sainati S; Roth-Schechter B; MacIntyre J
    Drug Metab Dispos; 1998 Jul; 26(7):617-22. PubMed ID: 9660843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
    DeVane CL; Donovan JL; Liston HL; Markowitz JS; Cheng KT; Risch SC; Willard L
    J Clin Psychopharmacol; 2004 Feb; 24(1):4-10. PubMed ID: 14709940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.
    Miura M; Lawson DC; Clary EM; Mangel AW; Pappas TN
    Dig Dis Sci; 1999 Jan; 44(1):20-4. PubMed ID: 9952218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers.
    Zhi J; Moore R; Kanitra L; Mulligan TE
    J Clin Pharmacol; 2003 Apr; 43(4):428-35. PubMed ID: 12723464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.